Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 51,059,000	$ 29,316,000
Accounts receivable	262,000	586,000
Prepaid expenses and other	1,791,000	1,135,000
Total current assets	57,840,000	31,190,000
Equipment, net	3,002,000	2,206,000
Deposits and other	888,000	197,000
Total assets	61,730,000	33,593,000
Current liabilities:
Accounts payable	9,163,000	4,469,000
Accrued compensation and related benefits	1,901,000	1,065,000
Accrued clinical trial related costs	1,276,000	1,453,000
Accrued expenses	461,000	425,000
Accrued license fee expense	0	1,900,000
Deferred revenue - Healios	0	250,000
Total current liabilities	15,475,000	10,083,000
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at December 31, 2018 and 2017	0	0
Common stock, $0.001 par value; 300,000,000 shares authorized; 144,292,739 and 122,077,453 shares issued and outstanding at December 31, 2018 and 2017, respectively	144,000	122,000
Additional paid-in capital	416,014,000	373,884,000
Accumulated deficit	(373,042,000)	(350,630,000)
Total stockholders’ equity	43,116,000	23,376,000
Total liabilities and stockholders’ equity	61,730,000	33,593,000
Healios License Agreement
Current assets:
Accounts receivable	1,108,000	153,000
Unbilled accounts receivable from Healios	3,620,000	0
Current liabilities:
Deposit from Healios	2,000,000	0
Deferred revenue - Healios	674,000	521,000
Advance from Healios	$ 3,139,000	$ 134,000